Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/22/25 16:31 | 9/18/25 | ACHV | Health | Diagn | In Vitro & In Vivo Diagnostic | Oki Mark K | WA | O | CFO | 1 | S.d | -146 | 2.92 | 0 | -50 | 128 | D | |||||||||||||||
9/22/25 16:29 | 9/18/25 | ACHV | Health | Diagn | In Vitro & In Vivo Diagnostic | Stewart Richard Alistair | WA | DO | CEO | 1 | S.d | -378 | 2.92 | 0 | -130 | 230 | D | |||||||||||||||
9/8/25 16:59 | 9/4/25 | ACHV | Health | Diagn | In Vitro & In Vivo Diagnostic | Wan Jerry | A1 | O | Principa | 1 | S.d | -39 | 2.77 | 0 | -14 | 33 | D | |||||||||||||||
9/8/25 16:54 | 9/4/25 | ACHV | Health | Diagn | In Vitro & In Vivo Diagnostic | King Thomas Braxton | WA | D | 1 | S.d | -387 | 2.77 | 0 | -140 | 315 | D | ||||||||||||||||
9/8/25 16:51 | 9/4/25 | ACHV | Health | Diagn | In Vitro & In Vivo Diagnostic | Jacobs Cindy | WA | O | P,CMO | 1 | S.d | -77 | 2.77 | 0 | -28 | 116 | D | |||||||||||||||
9/8/25 16:39 | 9/4/25 | ACHV | Health | Diagn | In Vitro & In Vivo Diagnostic | Xinos Jaime | WA | O | Chief Co | 1 | S.d | -58 | 2.77 | 0 | -21 | 74 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |